Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Xbrane Biopharma AB is a commercial phase Swedish biopharmaceutical company specializing in the development and manufacturing of biosimilars. Their primary focus is on creating high-quality, cost-effective alternatives to originator biologic drugs, thereby increasing patient access to essential medicines. Xbrane leverages its patented protein production platform technology to develop a pipeline of biosimilar candidates targeting various therapeutic areas, including oncology and immunology. The company has a strategic goal to become a global leader in the biosimilars market through in-house development, manufacturing partnerships, and commercial collaborations.
The headquarters in Solna serves as the central hub for Xbrane's research and development activities, corporate management, business development, and administrative functions.
Located in a prominent life science cluster, providing access to talent, research institutions like the Karolinska Institutet, and a vibrant biotech ecosystem. The facilities likely include advanced laboratories for protein engineering and process development.
Xbrane fosters an innovative, collaborative, and scientifically-driven work environment. The culture emphasizes quality, efficiency, and a commitment to advancing healthcare through biosimilars.
The Solna headquarters is strategically positioned to leverage Sweden's strong pharmaceutical research landscape and serves as the command center for Xbrane's global ambitions in the biosimilar space.
Xbrane Biopharma AB supports its functions globally through a combination of in-house expertise and strategic partnerships. Its research and development are centered in Sweden, while manufacturing capabilities are often established through collaborations with contract development and manufacturing organizations (CDMOs) in regions like Italy. Xbrane aims for global commercialization of its biosimilars, engaging in licensing and distribution agreements to reach patients worldwide. Clinical trials for their products are conducted across multiple countries to meet regulatory requirements for international markets.
Retzius Väg 8
Solna
Stockholm County
Sweden
Address: Via Settevene Palo, Nuova Km 23,600, 03012 Anagni FR, Italy (Note: This is likely a primary manufacturing partner site, e.g., with AGC Biologics, rather than a direct Xbrane office. Xbrane also lists 'Xbrane Biopharma S.r.l.' in Italy.)
Serves as a key manufacturing hub for supplying European and potentially global markets, leveraging established pharmaceutical infrastructure and expertise in biologic drug production.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, xbrane-bioscience-ab' leadership includes:
xbrane-bioscience-ab has been backed by several prominent investors over the years, including:
Xbrane Biopharma has seen key appointments in the last 12-18 months, strengthening its financial, legal, and compliance leadership as it progresses with its biosimilar portfolio.
Discover the tools xbrane-bioscience-ab uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Xbrane Biopharma AB commonly uses the firstname.lastname@xbrane.com email format. This is a prevalent structure in many Swedish and European companies.
firstname.lastname@xbrane.com
Format
martin.amark@xbrane.com
Example
85%
Success rate
Xbrane Biopharma AB • 2024-05-23
Xbrane released its Q1 2024 interim report, highlighting progress in its biosimilar development programs and financial performance. Key updates included advancements in the Ximluci® (ranibizumab) commercialization and pipeline developments....more
Xbrane Biopharma AB • 2024-02-22
The company published its full-year 2023 report, summarizing achievements such as the launch of Ximluci® in Europe, progress with FDA for US market approval, and continued development of its biosimilar pipeline, including an ustekinumab biosimilar....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including xbrane-bioscience-ab, are just a search away.